Total revenues for Q4FY18 were at Rs7.5bn (est. Rs8.5bn) were down 4.5% YoY and up 6.4% on a QoQ basis with a double digit growth in the pharma portfolio (ex GST and divestments/ discontinued portfolio). EBITDA margins improved to 20.7% given improved product mix and curtailment in OE. PAT was in-line with estimates up...